SITEMAP
Looking for something in particular?
Pages
Sitemap
Careers
Featured News
News
- Vaccitech Announces Pricing of Initial Public Offering
- Vaccitech Appoints Joseph Scheeren, PharmD, to its Board of Directors
- Vaccitech Doses First Patient in HPV001, a Phase 1/2 Clinical Trial of VTP-200 Immunotherapeutic for High-risk Persistent HPV Infection
- Vaccitech Completes $168 Million Series B Financing to Advance Three Clinical Programs Through Phase 2 Results
- Vaccitech Appoints Two Independent Board Directors
- Vaccitech Doses First Patient in HBV002, a Phase 1b/2a Clinical Trial of VTP-300 Immunotherapeutic Candidate for Chronic HBV Patients
- European Medicines Agency recommends conditional marketing authorisation to ChAdOx1 coronavirus vaccine
- Oxford University and Vaccitech welcome UK regulatory emergency use authorisation of coronavirus vaccine
- First peer-reviewed results of Phase 3 human trials of Oxford vaccine demonstrate efficacy
- Oxford University breakthrough on global COVID-19 vaccine
- Oxford coronavirus vaccine produces strong immune response in older adults
- Vaccitech expands management team with hires including CMO and CFO
- University of Oxford and Vaccitech to present at the ESMO Virtual Congress
- Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups
- Vaccitech receives government grant for COVID-19 vaccine research
- Clinical trial data shows Oxford University’s COVID-19 vaccine produces strong immune response
- First participant dosed in Phase 1 clinical study with VTP-300 immunotherapeutic to treat chronically infected Hepatitis B patients
- Vaccitech and Oxford University announce landmark partnership with AstraZeneca for the development and large-scale distribution of the COVID-19 vaccine candidate
- Oxford COVID-19 vaccine begins human trial stage
- Vaccitech to Present at Solebury Trout Virtual Investor Conference
- Vaccitech and Oxford University Announce Promising Phase 2a Data on Prostate Cancer Immunotherapy
- Phase 2 Clinical Results for Vaccitech’s Universal Influenza A Vaccine
- New MERS Coronavirus vaccine clinical trial starts in Saudi Arabia
- Vaccitech Oncology Limited enters collaboration with Cancer Research UK to fund a Phase I/IIa clinical trial as first-line NSCLC therapy
- Vaccitech provides update on clinical progress for its two Phase 2 Universal Influenza studies
- Vaccitech to present clinical development of Universal Influenza A Vaccine (VTP-100) in pandemic and seasonal indications at World Vaccine Congress Europe
- Vaccitech Appoints Bill Enright as New Chief Executive Officer
- Vaccitech Appoints Chief Medical Officer to Oversee Development of Growing Clinical Pipeline of T Cell-Inducing Viral Vector Vaccines
- Vaccitech Universal flu vaccine passes Phase 2b clinical development milestones
- ProBioGen and Vaccitech Sign License Agreement for ProBioGen’s Technology Platform
- Vaccitech Awarded BARDA contract valued at $8.6M to conduct Phase II trial for Influenza Vaccine
- Vaccitech receives £6M investment from GeneMatrix and Korea Investment Partners
- Update: INVICTUS Study
- Vaccitech licenses MERS rights to Oxford University
- New UK-China biotech collaboration to develop shingles vaccine
- VANCE: First in Human Phase I Study of a Novel ChAdOx1-MVA 5T4 Vaccine
- Phase 1 Data on the Vaccitech Prostate Cancer Vaccine Presented at ASCO 2018
- Universal Flu Vaccine Data Presented at NFID 2018
- Flu vaccine Study Recruits First Participants
- Vaccitech secures £20m Series A with GV, OSI and Sequoia China
- World-First NHS Trial For Universal Flu Vaccine
- Vaccitech Launch RIVET Study
- Vaccitech Feature in Jenner Institute Autumn 2016 Newsletter
- OBN Awards 2016: Vaccitech Announced as Finalists
- Dr Steve Chatfield Joins Vaccitech
Uncategorized